RetiSpec is developing an AI-driven retinal imaging system for the early detection of Alzheimer's disease through a simple eye exam. This technology enables the identification of neurodegenerative disease markers non-invasively, facilitating timely diagnosis and improving patient outcomes.
Funding
$17.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Alzheimer's disease detection typically relies on expensive, invasive, or inaccessible methods, hindering early diagnosis and timely intervention. Current diagnostic approaches often involve lengthy cognitive assessments, costly brain scans, or invasive cerebrospinal fluid analysis, limiting widespread screening and delaying treatment initiation.
Solution
RetiSpec is developing an AI-powered retinal imaging system that enables early detection of Alzheimer's disease through a non-invasive eye exam. The technology uses hyperspectral imaging to identify specific biomarkers in the retina that are indicative of neurodegenerative changes associated with Alzheimer's. By analyzing these retinal biomarkers with proprietary AI algorithms, RetiSpec aims to provide a rapid, affordable, and scalable solution for early Alzheimer's screening at the point of care. This approach facilitates timely diagnosis, improves patient outcomes, and supports the development of more effective treatments.
Target Audience
The primary target audience includes healthcare providers, neurologists, ophthalmologists, and memory clinics seeking a cost-effective and accessible tool for early Alzheimer's detection, as well as pharmaceutical companies involved in Alzheimer's drug development.
Features
- Hyperspectral retinal imaging to capture detailed spectral data from the retina
- AI-driven analysis of retinal biomarkers for early detection of Alzheimer's disease
- Non-invasive and rapid eye exam procedure
- Point-of-care testing for accessible and convenient screening
- Scalable technology for widespread implementation